Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen vaccine + nab-paclitaxel/durvalumab/tremelimumab in metastatic TNBC
NCT03606967Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NeoSLP in triple-negative breast cancer (TNBC), sponsored by National Cancer Institute. Started Apr 2021; status: recruiting.
02
Drugs
NeoSLP
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03606967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606967.